Medtech & Chronic-Disease Diagnostics
Distinct from our femtech spotlight — remote monitoring and diagnostics for the chronic conditions that rise with age.
global medtech market, 2025 to 2032
~6.5% annual growth (CAGR).
raised across 52 medtech deals
12 months to July 2026; median round $40M.
diagnostic devices’ funding pattern
High deal visibility, lower capital intensity — smaller cheques, more of them.
Inside the category
Wearables & remote monitoring
Continuous, at-home tracking replacing periodic clinical visits.
- Oura
- VitalConnect
- BioIntelliSense
Point-of-care diagnostics
Faster, more accessible testing outside traditional labs.
- Butterfly Network
- Sight Diagnostics
- Healthy.io
Why this fits women investors specifically
This sits deliberately apart from our femtech spotlight: chronic disease and remote monitoring aren’t reproductive-health-specific, but women are disproportionately household health-decision-makers and, per this site’s own research, the investors most likely to bring a values or gender lens to healthcare broadly — not only women’s-health-specific categories.
How to get exposure
Diagnostic-device deals tend to be smaller and more numerous than therapeutics deals — more entry points at lower cheque sizes for direct angel investing, alongside broader medtech-focused generalist funds.
The case against
Diagnostics has a structural problem that does not show up in the product: someone has to pay for the test, and in most health systems that someone is not the patient. Reimbursement decisions by insurers and national health bodies determine whether a clinically excellent device becomes a business, and those decisions arrive slowly and are not guaranteed by regulatory clearance. Remote-monitoring companies also compete with features that platform incumbents can ship for free. Smaller cheque sizes make entry easy here, which is not the same as making the outcome likelier.
How this category returns capital
Exits are dominated by trade sales to large device and diagnostics manufacturers, who typically buy after regulatory clearance and after a reimbursement pathway is established — two gates that add years. Public listings happen but are cyclical and concentrated in the largest names. The practical consequence is that the milestone driving a markup is regulatory and administrative rather than commercial, so a position can look static for a long time and then reprice sharply. Diligence effort is better spent on the reimbursement plan than on the technology.
What to weigh before writing a cheque
- Diagnostics get a large share of deal count but a small share of total capital — many companies compete for smaller cheques rather than a few capturing most funding.
- Regulatory clearance (FDA and equivalents) is a real, time-consuming gate for anything touching clinical diagnosis, unlike consumer wellness wearables.
Sources
Figures reflect the most recent public reporting as of 2026. Named companies are illustrative of funding activity, not investment recommendations.